NCT00193154

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).

Detailed description

Upon determination of eligibility, all patients will receive: Tarceva + Avastin

Conditions

• Kidney Cancer

Interventions

Type	Name	Description
DRUG	OSI-774	150mg PO, days 1-28, cycle repeated every 28 days
DRUG	Bevacizumab	10mg/kg, IV infusion, Days 1 and 15, 28 day cycles

Timeline

• Start date: 2003-02-01
• Primary completion: 2004-01-01
• Completion: 2014-03-01
• First posted: 2005-09-19
• Last updated: 2014-04-01

Locations

2 sites across 1 country: United States